Melanotan I vs Melanotan II: Complete Comparison Guide

TL;DR — The 90-Second Answer Melanotan I and Melanotan II are both melanocortin receptor agonists that stimulate melanin production, but differ fundamentally in specificity and systemic effects. Melanotan I selectively activates melanocortin-1 receptors to drive tanning while minimizing MC4R activation, producing pigmentation without significant sexual function or appetite changes. Melanotan II is a non-selective agonist activating MC1R, MC3R, MC4R, and MC5R simultaneously, resulting in tanning alongside pronounced libido enhancement, appetite suppression, and metabolic effects. Melanotan I is FDA-approved as Scenesse for erythropoietic protoporphyria; cosmetic use remains investigational. Melanotan II is unapproved and research-only. For users seeking isolated tanning, Melanotan I offers specificity with lower systemic burden; those desiring multi-system metabolic and sexual effects typically choose Melanotan II. Both require careful dose titration, mole monitoring, and physician oversight. Afamelanotide (melanotan-1) is FDA-approved as Scenesse for erythropoietic protoporphyria (EPP). Its use for tanning or other cosmetic purposes is not FDA-approved and is for research purposes only. Any compound without current FDA approval is for research and educational purposes only. Do not self-administer unapproved substances. Consult a licensed healthcare provider before use. This content does not replace medical advice.

---

At a Glance: Key Differences

---

What Is Melanotan I?

Melanotan I is an alpha-melanocyte-stimulating hormone (α-MSH) analog engineered to selectively activate melanocortin-1 receptors without triggering broader melanocortin signaling. Its primary function is stimulating melanogenesis—melanin production in skin cells—to generate a tan independently of UV exposure. The key advantage over broader-acting melanocortin agonists is its selectivity: Melanotan I achieves pigmentation while limiting activation of melanocortin-4 receptors (MC4R), which modulate sexual function and appetite. This specificity eliminates unwanted metabolic or sexual side effects, making it ideal for users prioritizing isolated cosmetic tanning. Melanotan I is clinically approved as Scenesse (afamelanotide) for erythropoietic protoporphyria, a genetic photosensitivity disorder, and provides measurable photoprotection. For cosmetic tanning applications, it remains investigational. Standard protocols involve a loading phase of 4–8 weeks at daily dosing, followed by maintenance at 1–2 times weekly. Side effects are typically mild: nausea, flushing, fatigue, and increased freckling.

---

What Is Melanotan II?

Melanotan II is a synthetic melanocortin receptor agonist with a broader, non-selective pharmacology than Melanotan I. Rather than targeting a single receptor subtype, Melanotan II activates multiple melanocortin subtypes—MC1R, MC3R, MC4R, and MC5R—producing cascading physiological effects beyond skin pigmentation. MC1R activation generates melanin and tanning; MC4R activation modulates sexual function and appetite; MC3R and MC5R involvement influences energy homeostasis and metabolic rate. This multi-receptor activity attracts users seeking convergent benefits: enhanced tanning alongside heightened libido and appetite suppression. However, the broader mechanism amplifies systemic side effects including nausea, flushing, darkened moles, and spontaneous erections. Melanotan II requires UV exposure for full tanning efficacy and demands conservative dose titration—most users begin at 0.25mg to assess tolerance. Unlike Melanotan I, Melanotan II remains FDA-unapproved and is strictly a research compound. Its effects are more pronounced and less predictable, necessitating careful medical supervision.

---

Mechanism of Action: How They Work Differently

The mechanistic distinction between Melanotan I and Melanotan II directly explains their divergent clinical profiles and user experiences. Melanotan I functions as a selective agonist of the melanocortin-1 receptor (MC1R), a G-protein-coupled receptor expressed predominantly on melanocytes. By targeting MC1R specifically, Melanotan I stimulates melanogenesis—the enzymatic synthesis and deposition of melanin—while limiting off-target activation of other melanocortin receptors, particularly the broadly distributed MC4R. This selectivity translates to robust tanning without the sexual or metabolic cascade effects that arise from broader melanocortin signaling. Research confirms that α-MSH analogs like Melanotan I provide systemic photoprotection in photosensitive disorders (PMID: 20969564), validating the selectivity and safety profile of the MC1R-agonist approach. Melanotan II, conversely, functions as a non-selective agonist across the melanocortin receptor family. Its simultaneous activation of MC1R (skin pigmentation), MC4R (sexual arousal and appetite regulation), and MC3R/MC5R (energy expenditure and metabolic rate) produces a compound physiological effect: enhanced tanning paired with spontaneous erections, decreased appetite, and elevated energy metabolism. This broader activity creates opportunities for multi-system benefit but elevates the risk of unintended consequences and side effects. Clinical literature on melanotropic peptides underscores the complexity of melanocortin signaling and the importance of receptor selectivity in predicting outcomes (PMID: 20545686). For users prioritizing isolated cosmetic effects, Melanotan I's selective approach minimizes systemic exposure; those seeking convergent metabolic and reproductive benefits may find Melanotan II's broader activity aligned with their goals—though at increased side effect cost.

---

Use Cases: Who Should Choose Which?

Melanotan I and Melanotan II serve distinct user populations based on their mechanistic profiles and desired outcomes. Melanotan I suits individuals seeking a cosmetic tan without confounding systemic effects. This includes users concerned about unwanted sexual function changes, those managing appetite sensitivity due to existing health conditions or concurrent supplement use, or individuals using other compounds that might interact poorly with MC4R activation. Professionals in appearance-sensitive fields appreciate Melanotan I's ability to deliver cosmetic improvement without the unpredictability of spontaneous erections or appetite suppression in professional settings. Melanotan I's role in providing photoprotection (PMID: 20969564) makes it relevant for individuals with documented photosensitivity disorders or those interested in UV-independent skin protection. Melanotan II appeals to a different demographic: users interested in the convergence of tanning, enhanced sexual function, and appetite control. Biohackers and longevity-focused individuals often select Melanotan II for its multi-system effects on reproductive function, appetite regulation, and energy metabolism. Performance-oriented athletes appreciate the appetite suppression and libido enhancement alongside tanning effects. However, Melanotan II demands greater vigilance due to its broader mechanism; unexpected systemic effects are more likely, requiring careful monitoring and conservative dose titration. Both peptides necessitate physician oversight before initiation, particularly given skin monitoring requirements and serious contraindications including melanoma history, pregnancy, and cardiovascular disease. The choice hinges on whether a user prioritizes isolated cosmetic tanning or seeks broader metabolic and reproductive function modification.

---

Dosing & Protocol Notes

Melanotan I administration begins at 0.5mg subcutaneously, typically in the evening via abdominal injection. The loading phase spans 4–8 weeks with daily dosing, after which maintenance transitions to 1mg administered 1–2 times weekly. Maintenance dose caps at 1mg to minimize side effect accumulation and optimize safety. Melanotan II starts significantly lower at 0.25mg—a critical distinction reflecting its broader receptor activity and higher side effect potential. Titration must be gradual; many users advance by 0.25mg increments over days or weeks to assess tolerance before reaching maintenance doses of 0.5–1mg daily. Both are injected subcutaneously in the evening; Melanotan I uses the abdomen, while Melanotan II can use the abdomen or thigh. Physician supervision is mandatory before initiation to establish baseline skin phototype, screen for melanoma history, and establish skin monitoring protocols. Users must document mole changes, freckling, or other skin alterations at regular intervals; any changes warrant immediate dermatologic evaluation. Nausea and flushing are common during loading phases and typically resolve with continued use. Hydration management supports nausea tolerance. Neither peptide should be initiated without medical oversight, baseline informed consent, and clear understanding of research status and risks.

Important: All dosing must be supervised by a licensed physician. Melanotan I and Melanotan II is not FDA-approved for human use and is for research and educational purposes only. This content does not replace medical advice.

---

Can They Be Combined?

Published literature does not directly address the safety or efficacy of combining Melanotan I and Melanotan II. Theoretical concerns include compounded and unpredictable melanocortin receptor activation: combining a selective MC1R agonist with a non-selective agonist could amplify both targeted tanning effects and off-target effects unpredictably. Simultaneous use would likely intensify common side effects (nausea, flushing, appetite suppression) and amplify sexual function changes. Since both compounds activate MC1R while Melanotan II also activates MC3R, MC4R, and MC5R, the combination may produce redundant tanning effects without obvious synergy—creating risk without clear benefit. Data remains limited on this combination. Any decision to stack these peptides would require extensive medical supervision, comprehensive baseline monitoring, and explicit informed consent regarding unknown risks. Most practitioners and informed users regard these peptides as alternatives rather than complementary compounds and do not recommend concurrent use without direct physician guidance and deep understanding of research status.

---

Research Citations

All citations verified against PubMed at time of generation.

1. Systemic photoprotection in solar urticaria with alpha-melanocyte-stimulating hormone analogue — PMID 20969564

*Demonstrates that selective MC1R agonism (the mechanism of Melanotan I) provides measurable photoprotection in photosensitive disorders, supporting the therapeutic and protective potential of the selective α-MSH analog approach.*

1. Melanotropic peptides: more than just Barbie drugs and sun-tan jabs — PMID 20545686

*Comprehensive clinical review of melanocortin agonists including both selective and non-selective compounds, contextualizing the mechanistic and clinical differences between Melanotan I's selective approach and Melanotan II's non-selective multi-receptor activation.*

---

Frequently Asked Questions

Which is more effective for achieving a cosmetic tan?

Both Melanotan I and Melanotan II stimulate melanin production and can generate a tan, but effectiveness depends on user goals and tolerance for systemic effects. Melanotan I requires UV exposure as an adjunct and is valued for isolated pigmentation without systemic changes. Melanotan II also requires UV exposure but may produce more dramatic tanning intensity due to its non-selective receptor activation; however, this comes with higher side effect potential. For cosmetic tanning alone with minimal systemic disruption, Melanotan I offers sufficient efficacy. Melanotan II suits users willing to accept broader systemic effects in exchange for intensity and multi-system benefits.

What is the key mechanistic difference between Melanotan I and Melanotan II?

Melanotan I selectively activates melanocortin-1 receptors (MC1R) to drive melanin production while minimizing off-target receptor activation, particularly MC4R. Melanotan II is a non-selective agonist that simultaneously activates MC1R, MC3R, MC4R, and MC5R, producing tanning alongside effects on libido, appetite regulation, and energy metabolism. This difference explains why Melanotan I causes minimal sexual or metabolic side effects while Melanotan II produces more pronounced systemic changes affecting sexual function, appetite, and energy expenditure.

Can Melanotan I and Melanotan II be taken together?

No published data supports combining Melanotan I and Melanotan II concurrently. The theoretical concern is compounded and unpredictable melanocortin receptor activation—using both simultaneously would likely intensify nausea, flushing, appetite suppression, and sexual function effects without clear additional benefit. Since both activate MC1R (with Melanotan II adding MC3R, MC4R, and MC5R activation), the combination would create redundant tanning effects while amplifying side effects. Melanotan I and Melanotan II are best considered alternatives rather than complementary compounds. Any consideration of concurrent use requires direct medical supervision and explicit informed consent.

Which has a better safety profile?

Melanotan I generally has a more favorable safety profile due to its selective MC1R mechanism, which minimizes off-target systemic effects. Its side effects—nausea, flushing, fatigue, and increased freckling—are typically mild and manageable. Melanotan II's non-selective activity increases the likelihood of pronounced side effects including appetite suppression and spontaneous erections, requiring more cautious titration and monitoring. Both peptides carry serious contraindications including melanoma history and pregnancy, and both require regular skin monitoring for mole darkening. Medical supervision is mandatory for both compounds, but Melanotan I's narrower mechanism profile generally translates to fewer unexpected systemic complications.

How does Alethea Health help track Melanotan I or Melanotan II protocols?

Alethea Health is a peptide protocol tracker designed to systematically monitor peptide administration, track side effects, manage dosing schedules, and document outcomes over time. For Melanotan I and Melanotan II users, Alethea Health enables structured logging of injection dates, doses, injection sites, side effect severity and duration, skin changes (mole darkening, freckling, overall tanning progress), and personal response patterns. This comprehensive data supports informed decision-making, facilitates communication with healthcare providers during medical supervision, ensures accountability throughout loading and maintenance phases, and helps users identify dose optimization opportunities while maintaining safety oversight.

---

Track Your Results with Alethea Health

Whether you're researching Melanotan I, Melanotan II, or both, tracking your protocol and biomarkers is the fastest path to understanding what works for your biology.

Start tracking your peptide protocol →

Alethea Health lets you log doses, side effects, and lab results — then surfaces patterns so you and your provider can make data-driven decisions.

---

All peptide guides · Free dose calculator

Educational reference only — not medical advice. Work with a qualified clinician.